Skip to Main Content

Paper Details

Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Prostate
9
2022
AR, AR target gene, AR variants, Abiraterone, CRPC, CRPC cell, CRPC clones, CYP17A1, Castration, Castration-resistant prostate cancer, GR, H295R, H295R xenografts, PSA, VCaP, VCaP cells, VCaP tumours, VCaP xenografts, abiraterone, androgen, androgen receptor, androgen receptor variants, androgens, castration-resistant prostate cancer, coculture models, enzalutamide, glucocorticoid receptor, human, human adrenal cells, mice, noncastrate tumours, patient, prostate and adrenal tumours, steroid, steroids, tumour, tumours
Author NameAffiliation
Wiebke ArltSchool of Clinical and Experimental Medicine, University of Birmingham
Guido Jenster
  • 1 - 2

Datasets

Release 1.2